
Lonza, BioWa Sign Licensing Agreement
BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.
BioWa and
Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System. The GS System includes Lonza’s host cell line, CHOK1SV. Potelligent Technology is designed to improve the potency and efficacy of therapeutic antibodies by improving antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.
MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent Technology. Today’s agreement incorporates Lonza’s technology to the existing Potelligent Technology.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.